Decoding the Blueprint: New Subtypes in Hereditary Breast Cancer Genomics

The Hidden Errors in Hereditary Breast Cancer Genomics

Imagine your DNA is a massive architectural blueprint. Most research focuses on two missing pages—BRCA1 and BRCA2. But what happens when those pages are present, yet the building still collapses?

For years, patients with a family history of cancer but 'clean' BRCA tests faced a medical mystery. Doctors knew the risk was there but could not see the mechanism. This lack of clarity meant many received generic treatments that failed to hit the mark.

Researchers recently performed whole-genome sequencing on 129 of these 'BRCA-negative' cases. They measured mutational signatures and structural changes to see how these tumours actually behave. They found that hereditary breast cancer is not one disease, but at least four distinct genomic profiles.

• HRD: These tumours mimic BRCA mutations, making them likely sensitive to PARP inhibitors.
• MUT: High mutation loads that may trigger a strong immune response, suggesting immunotherapy potential.
• CN: These shuffle large DNA segments, showing sensitivity to traditional chemotherapy in lab tests.
• Stable: These tumours maintain a quieter, more organised genome.

The data suggests that shifting from simple gene tests to a 'genomic instability index' could change how we categorise risk. This index measures how a tumour breaks, rather than just which gene is at fault.

Future clinics might use these signatures to match patients with precise drugs. Instead of a one-size-fits-all approach, doctors could tailor therapy based on the specific way a patient's DNA has buckled under pressure.